Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05141721
- Locations
- 🇺🇸
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Advanced Research (Oncology & Hemotology Associates of West Broward), Tamarac, Florida, United States
🇺🇸Banner MD Anderson, Gilbert, Arizona, United States
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05116917
- Locations
- 🇩🇰
Herlev and Gentofte Hospital, Herlev, Denmark
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT05116202
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Conditions
- Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaRecurrent Endometrial Carcinoma
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT05112601
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05088889
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1
- Registration Number
- NCT05074992
- Locations
- 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05048212
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT05041062
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 17
- Registration Number
- NCT05014776
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 71
- Registration Number
- NCT05012254
- Locations
- 🇪🇸
Hospital Provincial de Castellón, Castelló de la Plana, Castellon, Spain
🇪🇸Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.